| SAVA (SAVA) | |||
|---|---|---|---|
| 1.32 0.03 (2.33%) | 05-22 12:35 | ||
| Open: | 1.3 | Pre. Close: | 1.29 |
| High: | 1.345 | Low: | 1.272 |
| Volume: | 134,262 | Market Cap: | 64(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 2.34 -10000000000 One year: 2.37 -10000000000 |
| Support: | Support1: 1.95 -10000000000 Support2: 1.62 -10000000000 |
| Resistance: | Resistance1: 2.00 -10000000000 Resistance2: 2.03 -10000000000 |
| Pivot: | -10000000000 |
| Moving Averages: | MA(5): MA(20): MA(100): MA(250): |
| MACD: | MACD(12,26): -10000000000.00 -10000000000 Signal(12,26,9): -10000000000.00 -10000000000 |
| %K %D: | %K(14,3): -10000000000.00 -10000000000 %D(3): -10000000000.00 -10000000000 |
| RSI: | RSI(14): -10000000000.00 -10000000000 |
| 52-Week: | High: 4.98 Low: 1.15 Change(%): |
| Average Vol(K): | 3-Month: -10000000000 10-Days: -10000000000 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SAVA ] has closed Bollinger Bands are 0% narrower than normal. |
| Company profile |
|---|
| Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | |
| % Held by Insiders | |
| % Held by Institutions | |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
